Semaglutide vs Survodutide

Head-to-head evidence comparison — which supplement is right for you?

Quick answerNo interaction data — ask a pharmacist

Semaglutide vs Survodutide: Semaglutide has the stronger overall evidence (8.5 vs 5.5/10); they're alternatives for manage weight — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.

Semaglutide Edges Ahead

Semaglutide wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.

Semaglutide2 wins

Survodutide0 wins

Which is right for you? Take the 60-second quiz Open in the full comparison tool

Sgl8.5

Semaglutide

Too few graded studiesLimited safety

Srv5.5

Survodutide

Too few graded studiesLimited safety

Evidence

Evidence Score

Best8.5/10

Studies: 455

Meta-analyses: 134

Level: Very Strong

Evidence Score

5.5/10

Studies: 33

Meta-analyses: 5

Level: Moderate

Research findings

Verdict

Too few graded studies

Top outcomes

Blood sugar & glycemic controlToo few graded studies197
Weight managementToo few graded studies182
Cardiovascular outcomesToo few graded studies58

Verdict

Too few graded studies

Top outcomes

Weight managementToo few graded studies23
Glucose & glycemic controlToo few graded studies19
Liver fat, MASH & fibrosisToo few graded studies11

Shared outcomes (2)

Outcomes where both Semaglutide and Survodutide have evidence — compare verdict strength side-by-side.

Weight managementToo few graded studies182Too few graded studies23
Glucose & glycemic controlToo few graded studies197Too few graded studies19

Dosage & timing

Recommended Dosage:

Prescription-only, clinician-titrated. Subcutaneous (Wegovy weight management: escalate to 2.4 mg once weekly; Ozempic diabetes: 0.5-2.0 mg once weekly). Oral (Rybelsus diabetes: 3-14 mg once daily). DO NOT self-dose.

Warnings

This is a PRESCRIPTION DRUG, not a dietary supplement — use only under a clinician's care for an approved medical indication.
US FDA labeling includes a boxed warning about thyroid C-cell tumors: semaglutide caused these tumors in rodents; relevance to humans is uncertain. Under the US label it is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2. For treatment in Germany or Austria, consult the current EU product information for the exact medicine’s locally approved indications, contraindications and warnings; discuss any thyroid history with the prescriber.
Risk of acute pancreatitis — discontinue and seek care for severe persistent abdominal pain.
Risk of gallbladder disease (gallstones, cholecystitis), particularly with rapid weight loss.
Gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation) are very common, especially during dose escalation.
Post-marketing reports of ileus (severely slowed gut motility).
May worsen pre-existing diabetic retinopathy, attributed to rapid improvement in glucose control — ensure ophthalmologic monitoring in patients with a history of diabetic retinopathy.
Weight loss includes loss of lean muscle mass — pair with resistance training and adequate protein.
FDA has warned about COMPOUNDED / grey-market semaglutide: risk of dosing errors, impurities, and unapproved salt forms. Use only pharmacy-dispensed product.
Not for cosmetic weight loss without a genuine medical indication.
May increase hypoglycemia risk when combined with insulin or sulfonylureas (dose adjustment needed).

Best Time:

Any time of day

Can take on empty stomach

Best Form:

Subcutaneous once-weekly injection (Ozempic / Wegovy)

Recommended Dosage:

SupStack does not provide a self-directed dosing protocol for Survodutide. A dose used in a clinical trial does not establish a safe consumer dose. Phase-2 trials used once-weekly subcutaneous injection with stepwise escalation up to 4.8-6.0 mg maintenance.

Warnings

INVESTIGATIONAL DRUG — survodutide is NOT a dietary supplement. The first phase-3 efficacy trials (SYNCHRONIZE-1, SYNCHRONIZE-MASLD) have reported positively but the SYNCHRONIZE-CVOT outcomes trial is still ongoing as of 2026; long-term safety, durability and hard clinical outcomes are unknown.
The results are genuinely promising (phase-3 ~12-13% weight loss at 76 weeks; phase-2 up to 62% MASH histologic improvement vs 14% placebo, with phase-3 confirming ≥30% liver-fat reduction in 84% vs 24%), but there are still no completed cardiovascular/renal/mortality outcome data.
Grey-market 'survodutide' sold online despite no approval is especially risky — it is an unapproved investigational drug with no clinical oversight, no identity/purity/sterility guarantee, and no dosing standard.
GLP-1-class effects apply: dose-related gastrointestinal events (which drove higher discontinuation), gallbladder events, a pancreatitis class concern, and lean-mass loss alongside fat loss.
Glucagon-receptor agonism produced modest heart-rate increases and has theoretical glucose/hepatic effects; cardiovascular consequences are not yet characterised (SYNCHRONIZE-CVOT ongoing).
Expected GLP-1-class thyroid C-cell (medullary thyroid carcinoma) warning applies pending long-term human data.

Best Time:

Once a week

Can take on empty stomach

Best Form:

Once-weekly subcutaneous injection (investigational only)

Safety

Limited safetyTie

Drug Interactions:

Other GLP-1 receptor agonists (severe)
Insulin and sulfonylureas (moderate)
Oral medications (general) (moderate)

Side Effects:

NauseaVomiting / diarrhea / constipationGallbladder disease (cholelithiasis / cholecystitis)

Contraindications:

Personal or family history of medullary thyroid carcinoma (MTC) (a contraindication under the US label)
Multiple Endocrine Neoplasia syndrome type 2 (MEN2) (a contraindication under the US label)

Limited safetyTie

Drug Interactions:

Other GLP-1 / incretin drugs (severe)
Oral medications (delayed gastric emptying) (moderate)
Insulin / insulin secretagogues (sulfonylureas) (moderate)

Side Effects:

Nausea / vomitingDiarrhoea / constipationIncreased heart rate

Contraindications:

Not a dietary supplement and not an approved drug — investigational; do not self-source grey-market vials
Personal/family history of medullary thyroid carcinoma or MEN 2 (expected GLP-1-class thyroid C-cell precaution, not a product-label contraindication: this investigational drug has no label, and not every approved GLP-1 product carries the US thyroid boxed warning)

Shared goals

Manage weightSemaglutide

Semaglutide88/100

Survodutide68/100

Manage blood sugarSemaglutide

Semaglutide85/100

Survodutide48/100

What you'll notice

🩸 Improved glycemic controlpositive

Weeks to months

⚖️ Substantial weight losspositive

Months (titrated over 16-20 weeks)

❤️ Reduced cardiovascular eventspositive

Months to years

🤢 GI adverse effects (very common)trade-off

Especially during dose escalation

⚖️ Weight loss (phase-2)positive

Progressive over 24-46 weeks

🫀 MASH improvement on biopsy (phase-2)positive

By 48 weeks

🩸 Improved glycemic controlpositive

By 16-46 weeks

🤢 Gastrointestinal adverse eventstrade-off

Especially during dose escalation

Key studies

Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1).

N Engl J Med (2021) · Rct · n=1961

Double-blind RCT in 1,961 adults with obesity/overweight WITHOUT diabetes, randomized 2:1 to subcutaneous semaglutide 2.4 mg/week or placebo plus lifestyle for 68 weeks

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT).

N Engl J Med (2023) · Rct · n=17604

Large cardiovascular-outcomes RCT: 17,604 patients with preexisting cardiovascular disease and overweight/obesity but WITHOUT diabetes

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6).

N Engl J Med (2016) · Rct · n=3297

Pre-approval cardiovascular-safety RCT in 3,297 patients with type 2 diabetes at high cardiovascular risk, semaglutide (0.5/1.0 mg/week) vs placebo for 104 weeks

All Semaglutide studies

A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.

N Engl J Med (2024) · Rct · n=293

48-week phase-2, double-blind, randomized, placebo-controlled trial in 293 adults with biopsy-confirmed MASH and fibrosis stage F1-F3, once-weekly subcutaneous survodutide 2.4/4.8/6.0 mg vs placebo with a 24-week rapid-escalation then 24-week maintenance design

Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.

Lancet Diabetes Endocrinol (2024) · Rct · n=387

Phase-2, double-blind, randomized, placebo-controlled dose-finding trial in 387 adults with obesity (BMI ≥27) across 43 centres in 12 countries, once-weekly subcutaneous survodutide 0.6-4.8 mg vs placebo for 46 weeks

Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.

Diabetologia (2024) · Rct · n=413

Phase-2, multicentre, double-blind, randomized, placebo-controlled dose-response trial in 413 adults with type 2 diabetes, once-weekly subcutaneous survodutide across six dose groups vs placebo, with an open-label semaglutide reference arm

All Survodutide studies

Frequently asked questions

Is Semaglutide better than Survodutide?

Semaglutide has a higher evidence score (8.5/10 vs 5.5/10) and wins in 2 of 3 categories.

Is Semaglutide or Survodutide better for manage weight?

For manage weight, Semaglutide has a higher relevance score (88 vs 68).

Can I take Semaglutide and Survodutide together?

No documented interaction was found in the data searched. This does not establish that this exact combination is safe.

Related comparisons

Semaglutide vs Tirzepatide Liraglutide vs Semaglutide AREDS2 Formula vs Semaglutide Dulaglutide vs Semaglutide Survodutide vs Whey Protein Survodutide vs Tirzepatide

Still deciding between Semaglutide and Survodutide?

The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.

Get your personalised pick Semaglutide details Survodutide details

Warnings

This is a PRESCRIPTION DRUG, not a dietary supplement — use only under a clinician's care for an approved medical indication.

US FDA labeling includes a boxed warning about thyroid C-cell tumors: semaglutide caused these tumors in rodents; relevance to humans is uncertain. Under the US label it is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2. For treatment in Germany or Austria, consult the current EU product information for the exact medicine’s locally approved indications, contraindications and warnings; discuss any thyroid history with the prescriber.

Risk of acute pancreatitis — discontinue and seek care for severe persistent abdominal pain.

Risk of gallbladder disease (gallstones, cholecystitis), particularly with rapid weight loss.

Gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation) are very common, especially during dose escalation.

Post-marketing reports of ileus (severely slowed gut motility).

May worsen pre-existing diabetic retinopathy, attributed to rapid improvement in glucose control — ensure ophthalmologic monitoring in patients with a history of diabetic retinopathy.

Weight loss includes loss of lean muscle mass — pair with resistance training and adequate protein.

FDA has warned about COMPOUNDED / grey-market semaglutide: risk of dosing errors, impurities, and unapproved salt forms. Use only pharmacy-dispensed product.

Not for cosmetic weight loss without a genuine medical indication.

May increase hypoglycemia risk when combined with insulin or sulfonylureas (dose adjustment needed).

Warnings

INVESTIGATIONAL DRUG — survodutide is NOT a dietary supplement. The first phase-3 efficacy trials (SYNCHRONIZE-1, SYNCHRONIZE-MASLD) have reported positively but the SYNCHRONIZE-CVOT outcomes trial is still ongoing as of 2026; long-term safety, durability and hard clinical outcomes are unknown.

The results are genuinely promising (phase-3 ~12-13% weight loss at 76 weeks; phase-2 up to 62% MASH histologic improvement vs 14% placebo, with phase-3 confirming ≥30% liver-fat reduction in 84% vs 24%), but there are still no completed cardiovascular/renal/mortality outcome data.

Grey-market 'survodutide' sold online despite no approval is especially risky — it is an unapproved investigational drug with no clinical oversight, no identity/purity/sterility guarantee, and no dosing standard.

GLP-1-class effects apply: dose-related gastrointestinal events (which drove higher discontinuation), gallbladder events, a pancreatitis class concern, and lean-mass loss alongside fat loss.

Glucagon-receptor agonism produced modest heart-rate increases and has theoretical glucose/hepatic effects; cardiovascular consequences are not yet characterised (SYNCHRONIZE-CVOT ongoing).

Expected GLP-1-class thyroid C-cell (medullary thyroid carcinoma) warning applies pending long-term human data.

Frequently asked questions

Is Semaglutide better than Survodutide?

Semaglutide has a higher evidence score (8.5/10 vs 5.5/10) and wins in 2 of 3 categories.

Is Semaglutide or Survodutide better for manage weight?

For manage weight, Semaglutide has a higher relevance score (88 vs 68).

Can I take Semaglutide and Survodutide together?

No documented interaction was found in the data searched. This does not establish that this exact combination is safe.